Potential Role of Kringle-Integrin Interaction in Plasmin and uPA Actions (A Hypothesis)

Abstract

We previously showed that the kringle domains of plasmin and angiostatin, the N-terminal four kringles (K1–4) of plasminogen, directly bind to integrins. Angiostatin blocks tumor-mediated angiogenesis and has great therapeutic potential. Angiostatin binding to integrins may be related to the antiinflammatory action of angiostatin. We reported that plasmin induces signals through protease-activated receptor (PAR-1), and plasmin-integrin interaction may be required for enhancing plasmin concentration on the cell surface, and enhances its signaling function. Angiostatin binding to integrin does not seem to induce proliferative signals. One possible mechanism of angiostatin's inhibitory action is that angiostatin suppresses plasmin-induced PAR-1 activation by competing with plasmin for binding to integrins. Interestingly, plasminogen did not interact with αvβ3, suggesting that the αvβ3-binding sites in the kringle domains of plasminogen are cryptic. The kringle domain of urokinase-type plasminogen activator (uPA) also binds to integrins. The uPA-integrin interaction enhances uPA concentrations on the cell surface and enhances plasminogen activation on the cell surface. It is likely that integrins bind to the kringle domain, and uPAR binds to the growth factor-like domain (GFD) of uPA simultaneously, making the uPAR-uPA-integrin ternary complex. We present a docking model of the ternary complex.

1. The Kringle Domains of Plasmin Interact with Integrins

The integrins are a superfamily of cell adhesion receptors that bind to extracellular matrix ligands, cell-surface ligands, and soluble ligands. They are transmembrane αβ heterodimers and at least 18 α and eight β subunits are known in humans, generating 24 heterodimers [1]. The α and β subunits have distinct domain structures, with extracellular domains from each subunit contributing to the ligand-binding site of the heterodimer. The sequence arginine-glycine-aspartic acid (RGD) was identified as a general integrin-binding motif, but individual integrins are also specific for particular protein ligands. Immunologically important integrin ligands are the intercellular adhesion molecules (ICAMs), immunoglobulin superfamily members present on inflamed endothelium and antigen-presenting cells. On ligand binding, integrins transduce signals into the cell interior; they can also receive intracellular signals that regulate their ligand-binding affinity.

Angiostatin, a proteolytic fragment of plasminogen, contains either the first three or four kringle domains of plasminogen and is a potent inhibitor of tumor-induced angiogenesis in animal models [2, 3]. Angiostatin has promising therapeutic potential and is now in clinical trials. Plasminogen is first converted to the two-chain serine protease plasmin by cleavage of a single Arg561-Val562 peptide bond by urokinase-type plasminogen activator (uPA), and plasmin serves as both the substrate and enzyme for the generation of angiostatin [4]. Several other mechanisms have been proposed for the generation of angiostatin from the plasminogen molecule [5]. The antiangiogenic functions of plasminogen kringles have been extensively studied using recombinant plasminogen kringles and kringle fragments produced by elastolytic processing of native plasminogen. Smaller fragments of angiostatin display differential effects on the suppression of endothelial cell growth [6].

We found that bovine arterial endothelial (BAE) cells adhere to angiostatin in an integrin-dependent manner and that integrins αvβ3, α9β1, and to a lesser extent α4β1, specifically bind to angiostatin. αvβ3 is a predominant receptor for angiostatin on BAE cells, since a function-blocking antibody to αvβ3 effectively blocks adhesion of BAE cells to angiostatin, but an antibody to α9β1 does not. ε-Aminocaproic acid, a Lys analogue, effectively blocks angiostatin binding to BAE cells, indicating that an unoccupied Lys-binding site of the kringles may be required for integrin binding. It is known that other plasminogen fragments containing three or five kringles (K1–3 or K1–5) have an antiangiogenic effect, but plasminogen itself does not. We found that K1–3 and K1–5 bind to αvβ3, but plasminogen does not. These results suggest that the anti-angiogenic action of angiostatin may be mediated via interaction with αvβ3. Angiostatin binding to αvβ3 does not strongly induce stress-fiber formation, suggesting that angiostatin may prevent angiogenesis by perturbing the αvβ3-mediated signal transduction that may be necessary for angiogenesis [7].

Plasmin, the parent molecule of angiostatin and a major extracellular protease, induces platelet aggregation, migration of peripheral blood monocytes, and release of arachidonate and leukotriene from several cell types [8]. We found that plasmin specifically binds to αvβ3 through the kringle domains and induces migration of endothelial cells. In contrast, angiostatin does not induce cell migration. Notably, angiostatin, anti-αvβ3 antibodies, RGD-peptide, and a serine protease inhibitor effectively block plasmin-induced cell migration. These results suggest that plasmin-induced migration of endothelial cells requires αvβ3 and the catalytic activity of plasmin and that this process is a potential target for the inhibitory activity of angiostatin [9].

We found that plasmin specifically interacts with integrin (α9β1) and that plasmin induces migration of cells expressing recombinant α9β1 (α9-Chinese hamster ovary (CHO) cells). Migration was dependent on an interaction of the kringle domains of plasmin with α9β1 as well as the catalytic activity of plasmin. Angiostatin, representing the kringle domains of plasmin, alone did not induce the migration of α9-CHO cells, but simultaneous activation of the G protein-coupled protease-activated receptor (PAR)-1 with an agonist peptide induced the migration on angiostatin, whereas PAR-2 or PAR-4 agonist peptides were without effect. Furthermore, a small chemical inhibitor of PAR-1 (RWJ 58259) and a palmitoylated PAR-1-blocking peptide inhibited plasmin-induced migration of α9-CHO cells. These results suggest that plasmin induces migration by kringle-mediated binding to α9β1 and simultaneous proteolytic activation of PAR-1 [10]. It is likely that other integrins that bind to plasmin may exert similar effects on plasmin signaling.

We propose a model (Figure 1) in which (1) upon plasminogen activation, integrin-binding site in plasmin is exposed. Note that plasminogen does not bind to integrins αvβ3 or α9β1. (2) Once activated, plasmin is able to bind to integrins on the cell surface through the kringle domains (since integrin-binding sites are exposed) and proteolytically activates PAR-1, which induces intracellular signaling. Plasmin is concentrated to the cell surface through integrin binding, and this process is probably critical since plasmin has much lower affinity to PAR-1 than thrombin. Angiostatin, in contrast, binds to integrins, but does not activate PAR-1. Angiostatin is expected to suppress plasmin action by competing with plasmin for binding to integrins.

Figure 1.

A model of plasmin-induced cell migration and the potential mechanism of angiostatin action. uPA activates plasminogen to plasmin pericellularly. Plasmin is accumulated on the cell surface by binding to integrins and stabilized. Free plasmin would be rapidly inactivated by circulating serine protease inhibitors (e.g., β2-antiplasmin). The catalytic activity of plasmin on the cell surface is directly involved in signal transduction, possibly through activating G-protein coupled PARs. The binding of the kringle domain may not be directly involved in signaling through integrin pathways. Angiostatin effectively blocks plasmin-induced cell migration possibly by competing with plasmin for binding to integrins. Aprotinin, a serine protease inhibitor, also effectively blocks migration. It should be noted that other antiangiogenic agents, RGD-peptide and anti-αvβ3, are effective inhibitors of this process.

It has been reported that integrins αMβ2 [11], αDβ2 [12], and α5β1 [13] bind to plasminogen, while we did not detect binding of αvβ3 or α9β1 to plasminogen. One possibility is that integrins αMβ2, αDβ2, and α5β1 recognize plasminogen in the ways different from those of αvβ3 or α9β1. Another possibility is that integrin-binding sites in plasminogen (perhaps kringle domains) are exposed in partially denatured plasminogen. Supporting the second possibility we observed that freshly prepared plasminogen did not significantly bind to αvβ3, but plasminogen binding to αvβ3 appeared to increase as plasminogen preparations aged (data not shown). This issue should be clarified in future studies.

In conclusion, the kringle domains in plasmin are involved in direct integrin binding, in addition to binding to the C-terminal Lysine residues of many proteins, and playing a role in inducing intracellular signals through proteolytic activation of PAR-1. The kringle-integrin interaction may enhance the cell surface concentration of plasmin, or directly induce intracellular signals through outside-in integrin signaling. Interestingly, plasminogen does not interact with integrins αvβ3 or α9β1 (possibly the integrin-binding sites are cryptic in plasminogen) (Figure 1) Based on our results on the plasmin kringle-integrin interaction, we hypothesized that the kringle domains of other serine proteases may interact with integrins and the interaction may play a role in their functions. Consistent with this idea, kringle domains from other proteins such as tissue-type plasminogen activator (tPA) [14] and apolipoprotein [15] have been reported to interact with integrins. This suggests that kringle-integrin interaction is a common mechanism in kringle-containing proteins.

2. uPA Kringle-Integrin Interaction

uPA is a highly restricted serine protease that converts the zymogen plasminogen to active plasmin. uPA binds with high affinity to a cell-surface uPA receptor (uPAR) that has been identified in many cell types. uPAR is a glycosylphosphatidylinositol- (GPI-) anchored 35–55 kDa glycoprotein. This system mediates pericellular proteolysis of extracellular matrix proteins including fibrin degradation (fibrinolysis) and plays an important role in cancer, inflammation, and immune responses [16–19]. The single chain form of uPA has three independently folded domains: the growth factor-like domain (GFD) (residue 1–46), kringle (residue 47–135) domain, and serine protease domain (residue 159–411). Enzymatic digestion of single chain-uPA yields an amino terminal fragment (ATF), which consists of the GFD and kringle domains, and the low molecular weight fragment (LMW-uPA), which consists of the serine protease domain. The uPAR-binding site of uPA is located in the GFD domain [20]; this binding is stabilized by the kringle [21]. It has generally been accepted that uPA signaling involves its binding to uPAR through its GFD [22].

uPA binding to uPAR on the cell surface facilitates activation of plasminogen to plasmin in vitro by increasing the rate of pro-uPA activation by plasmin, by decreasing the apparent Km of uPA to plasmin, and by increasing the Kcat/Km of uPA to plasmin [23]. It is interesting that uPA-knockout mice do not have major thrombotic disorders [24]. This is probably because of the redundant fibrinolytic function by tPA. Indeed, combined uPA and tPA knockout mice show extensive thrombotic disorders very similar to those observed in plasminogen-knockout mice, but these are rarely detected in animals lacking uPA or tPA alone [25]. In contrast to uPA, studies performed in uPAR-knockout mice do not really support a major role of uPAR in fibrinolysis. Fibrin deposits are found within the livers of mice with a combined deficiency in uPAR and tPA, but not in uPAR-knockout mice, indicating a minor role for uPAR in plasminogen activation [25]. The extraordinarily mild consequences of combined uPAR and tPA deficiency raised the question of whether there are other receptors for uPA that might facilitate plasminogen activation [19, 25].

Besides plasminogen activation, uPA has been shown to induce the adhesion and chemotactic movement of myeloid cells [26, 27], to induce cell migration in human epithelial cells [28] and bovine endothelial cells [29], and to promote cell growth [30–32]. Notably these signaling functions of uPA do not require its proteolytic activity. Several studies suggest that uPA has additional, unidentified cell-surface receptor(s) other than uPAR that are involved in signaling events. For example, blocking of uPA binding to uPAR using a monoclonal antibody or by depletion of cell surface uPAR with phosphatidylinositol-specific phospholipase C (PIPLC) did not inhibit uPA-induced mitogenic effects in smooth muscle cells [33]. uPA-induced mitogenic effects in melanoma cells are independent of high-affinity binding to uPAR, and this suggests the existence of a low-affinity binding site on this cell type based on the kinetic data [34]. The chemotactic action of uPA on smooth muscle cells depends on its kringle domain, and kinetic evidence indicates that these cells express a lower-affinity kringle receptor distinct from uPAR [35]. The isolated uPA kringle augments vascular smooth muscle cell constriction in vitro [36] and in vivo [37]. Taken together these observations all suggest that cells express uPA-binding proteins (other than uPAR) that mediate signaling from uPA.

We found that uPA binds specifically to integrin αvβ3 on CHO cells depleted of uPAR (Figure 2). The binding of uPA to αvβ3 required the uPA kringle domain (Figure 3). The isolated uPA kringle domain binds specifically to purified, recombinant soluble, and cell surface αvβ3, and other integrins (α4β1 and α9β1), and induces migration of CHO cells in an αvβ3-dependent manner. The binding of the uPA kringle to αvβ3 and uPA kringle-induced αvβ3-dependent cell migration is blocked by angiostatin. We studied whether the binding of uPA to integrin αvβ3 through the kringle domain plays a role in plasminogen activation. On CHO cell depleted of uPAR, uPA enhances plasminogen activation in a kringle and αvβ3-dependent manner (Figure 4). Endothelial cells bind to and migrate on uPA and uPA kringle in an αvβ3-dependent manner. These results suggest that uPA binding to integrins through the kringle domain plays an important role in both plasminogen activation and uPA-induced intracellular signaling. The uPA kringle-integrin interaction may represent a novel therapeutic target for cancer, inflammation, and vascular remodeling [38].

Figure 2.

uPA binding to the cell surface in an integrin αvβ3-dependent and uPAR-independent manner [38]. (a) and (b) Depletion of uPAR from the cell surface blocked uPA binding to uPAR-CHO cells, but did not affect uPA binding to β3-CHO cells. To deplete GPI-linked uPAR on the cell surface, β3-CHO, uPAR-CHO, or control mock-transfected CHO cells were treated with PIPLC. The treatment removed more than 95% of human uPAR from uPAR-CHO cells as determined by flow cytometry with anti-uPAR mAb 3B10 (data not shown). uPA was immobilized to wells of 96-well microtiter plates at the indicated coating concentrations, and incubated with cells without (a) or with (b) pretreatment with PI-PLC. Bound cells were quantified. (c) uPA binding to β3-CHO cells is specific to αvβ3 and the kringle domain. uPA (200 nM coating concentration) was immobilized to wells of 96-well microtiter plates and incubated with β3-CHO cells in the presence of mAb 16N7C2 (anti-β3), Ab 963 (anti-kringle), mAb UNG-5 (anti-LMW-uPA), or RGD or RGE peptides (100 μM).

Figure 3.

The kringle domain of uPA mediates binding to αvβ3. The uPA kringle domain was immobilized onto wells of 96-well microtiter plates at the indicated coating concentrations and incubated with β3-CHO, uPAR-CHO, or mock-CHO cells. The ability of the uPA fragments to support adhesion of these cells was determined [38].

Figure 4.

Integrin-dependent plasminogen activation on the cell surface. Parental CHO cells and β3-CHO cells in wells of 96-well plates were treated with PIPLC to deplete uPAR, and incubated with wt or delta kringle (ΔK) uPA in the cold binding buffer for 1 h at 4°C. The cells were washed with the binding buffer, and plasminogen activation was determined using Glu-plasminogen and SpectrozymePL chromogenic substrate at 37°C. We found that β3-CHO cells showed much higher ability to activate plasminogen in a manner dependent on the uPA added. Deletion of the kringle domain (with ΔK-uPA) markedly reduced the plasminogen activation on β3-CHO, indicating that αvβ3 and uPA-dependent plasminogen activation required the kringle domain of uPA. These results suggest that the binding of uPA kringle to integrin αvβ3 induces plasminogen activation [38].

We propose a model, in which the N-terminal GFD of uPA binds to uPAR and the kringle domain of uPA binds to integrins, leading to the uPAR-uPA-integrin ternary complex on the cell surface. It is likely that the ternary complex formation may be involved in uPA signaling and plasminogen activation. The isolated kringle or the isolated GFD domain may suppress uPA signaling or plasminogen activation by suppressing the process. Indeed isolated kringle domain or GFD have been shown to suppress tumorigenesis [39].

3. Another Example of the Role of αvβ3 in uPA Signaling: uPA Kringle and Integrin αvβ3 in Neutrophil Activation

It has been reported that antibody to integrin αvβ3 and RGD peptide suppress the signaling action of uPA in neutrophils, although it is unclear if this include direct uPA-αvβ3 interaction [40]. The study examined the ability of specific uPA domains to increase cytokine expression in murine and human neutrophils stimulated with lipopolysaccharides (LPS). Whereas the addition of intact uPA to neutrophils cultured with LPS increased mRNA and protein levels of interleukin-1β, macrophage-inflammatory protein-2, and tumor necrosis factor α, deletion of the kringle domain from uPA resulted in loss of these potentiating effects. Addition of purified uPA kringle domain to LPS-stimulated neutrophils increased cytokine expression to a degree comparable with that produced by single-chain uPA. Inclusion of the RGD but not the RGE peptide to neutrophil cultures blocked uPA kringle-induced potentiation of proinflammatory responses, demonstrating that interactions between the kringle domain and integrins are involved. Antibodies to the αv or β3 subunit or to αvβ3 heterodimer prevented uPA kringle-induced enhancement of expression of proinflammatory cytokines and also of adhesion of neutrophils to the uPA kringle domain. These results demonstrate that the kringle domain of uPA, through interaction with αvβ3 integrins, potentiates neutrophil activation.

4. A Docking Model of uPAR-uPA Kringle-Integrin Interaction

How does integrin αvβ3 interact with uPA kringle? This has recently been predicted by docking simulation [41]. They modeled the interaction of uPA on two integrins, αIIbβ3 in the open configuration and αvβ3 in the closed configuration. They found that multiple lowest energy solutions point to an interaction of the kringle domain of uPA at the boundary between α and β chains on the surface of the integrins. This region is not far away from peptides that have been previously shown to have a biological role in uPAR/integrins dependent signaling. They demonstrated that in silico docking experiments can be successfully carried out to identify the binding mode of the kringle domain of uPA on the scaffold of integrins in the open and closed conformation. Importantly they found that the binding mode is the same on different integrins and in both configurations. To get a molecular view of the system is a prerequisite to unravel the complex protein-protein interactions underlying uPA/uPAR/integrin mediated cell motility, adhesion, and proliferation, and to design rational in vitro experiments.

However, in their paper which amino acid residues in uPA kringle are involved in integrin interaction is unclear. Thus, we presented our model here (Figure 5). We performed docking simulation of the interaction between uPA kringle (PDB code 2URK) and integrin αvβ3 (PDB code 1L5G) using Autodock3. The simulation predicted the poses in which uPA kringle interacts with αvβ3 (docking energy −22.3 kcal/mol). The amino acid residues involved in the interaction are shown in Table 1. The uPA kringle-binding site in αvβ3 appears to be common to other known αvβ3 ligands. The uPA kringle-integrin complex was superposed with the ATF-uPAR complex (PDB code 2I9B). Our model predicts that integrin αvβ3 and uPAR can bind to ATF (GFD and kringle) simultaneously without steric hindrance. Obviously, it would be important to identify amino acid residues in uPA kringle that are critical for integrin binding by site-directed mutagenesis. In future studies, using uPA kringles that cannot bind to integrins or uPAR, it would be important to study the role of uPA kringle-integrin interaction in the proinflammatory action of uPA and to establish the role of uPAR in this process.

Figure 5.

A model of integrin, uPA kringle, and uPAR complex. We performed docking simulation of the interaction between uPA kringle (PDB code 2URK) and integrin αvβ3 (PDB code 1L5G) using Autodock3. The simulation predicted the poses in which uPA kringle interacts with αvβ3. The uPA kringle-integrin complex was superposed with the ATF-uPAR complex (PDB code 2I9B).

Table 1.

Amino acid residues involved in αvβ3-uPA kringle interaction in the docking model. Amino acid residues at the binding interface (within the 6 Angstrom) were selected using Swiss pdb viewer (v. 4.02).

αv	β3	uPA kringle
Ala149, Asp150, Tyr178, Gln214, Ala215, Ile216, Asp218, Asp219, Arg248	Tyr122, Ser123, Met124, Lys125, Asp126, Asp127, Asp179, Met180, Lys181, Thr182, Arg214, Arg216, Asp217, Ala218, Asp251, Ala252, Lys253, Thr311, Glu312, Asn313, Val314, Asn316, Val332, Leu333, Ser334, Met335, Asp336, Ser337	Ser47, Lys48, Thr49, Tyr51, Glu52, Gly53, Asn54, Gly55, His56, Phe57, Tyr58, Arg59, Tyr84, Asp90, Leu92, Gln93, Leu94, Asn104, Pro105, Asp106, Asn107, Arg108, Arg109, Arg110, Glu125

5. uPAR-Integrin Interaction

Previous studies suggest that uPAR directly binds to integrins [42–44]. How can our hypothesis explain this interaction? Our preliminary docking simulation studies of interaction between uPAR and integrin αvβ3 did not detect high-affinity αvβ3 binding sites in uPAR (not shown). In contrast the docking simulation of interaction between uPA kringle and αvβ3 predicted high affinity binding of αvβ3 to uPA kringle (as shown above). Since uPA binds to uPAR at high-affinity through GFD of uPA, one possibility is that previous studies detected interactions between the uPA-uPAR complex and integrins, in which integrins bind indirectly to uPAR through uPA kringle, but not those between uPAR and integrins. uPA is widely expressed in different cell types and tissues. This hypothesis should be rigorously tested in future studies.